<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960878</url>
  </required_header>
  <id_info>
    <org_study_id>2020S042</org_study_id>
    <nct_id>NCT04960878</nct_id>
  </id_info>
  <brief_title>The Effect of Synbiotics on the Upper Respiratory Tract Infection</brief_title>
  <official_title>The Effect of Synbiotics on the Upper Respiratory Tract Infection in Healthy Subjects: A Randomized Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gut microbiome manipulation to alter the gut-lung axis may potentially protect humans against&#xD;
      respiratory infections. However, clinical trials of synbiotics, one of the&#xD;
      microbiota-targeted intervention, in this regard is few. Therefore, this study aims to&#xD;
      examine the effect of synbiotics on the incidence and severity of upper respiratory tract&#xD;
      infection, gut microbiota composition and function, as well as biomarkers of immune function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Actual">January 5, 2021</completion_date>
  <primary_completion_date type="Actual">December 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of the upper respiratory tract infection</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of the upper respiratory tract infection</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of the upper respiratory tract infection</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The severity of the upper respiratory tract infection was assessed using the 24-item Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Paricipants were required to answer the question, &quot;Did you have any symptom of upper respiratory tract infection today&quot;? If someone answered &quot;yes&quot;, he/she was instructed to complete WURSS-24 surveys daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the gut mictobiota</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Changes in the composition, diversity, and function of gut mictobiota in feces will be measured by 16S rRNA gene sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of sIgA in saliva and feces</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of inflammatory cytokine</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Changes in the levels of fasting plasma inflammatory cytokine, including CRP, IL-1β, IL-6, IL-8, IL-10, TNF-α, and IFN-γ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the number of T, B, NK and monocytes populations</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Changes in the number of T-lymphocytes(CD45+CD3+), B-lymphocytes(CD45+CD19+), monocytes(CD45+CD14+), and natural killer cells(CD45+CD56+) in blood samples were evaluated by flow cytometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the subpopulation frequencies of blood lymphocyte and dendritic cells</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Changes in the subpopulation of blood lymphocytes (the levels of CD3+, CD4+, CD8+, and CD25+) and dendritic cells (the levels of CD3-CD19-CD56-HLA-DR+ CD11c+cells and CD3-CD19-CD56-HLA-DR+CD123+ cells ) in blood samples were evaluated by flow cytometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat composition</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the levels fasting plasma glucose</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of fasting plasma TC, TG, LDL, and HDL</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Upper Respiratory Tract Infection</condition>
  <condition>Gut Microbiota</condition>
  <condition>Immune Function</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.5 g maltodextrin in a sachet once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 g synbiotics supplement of Lactobacillus rhamnosus HN001 (1.5×10^11 CFU) , Bifidobacterium lactis HN019 (7.5×10^10 CFU), and 500mg fructooligosaccharides in a sachet once daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18-65 years；&#xD;
&#xD;
          -  good general health as determined by medical questionnaires;&#xD;
&#xD;
          -  BMI &lt;35 kg/m2;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known congenital or acquired immune defects；&#xD;
&#xD;
          -  allergies and other chronic or acute diseases requiring treatment；&#xD;
&#xD;
          -  subjects with chronic gastrointestinal diseases;&#xD;
&#xD;
          -  alcohol or drug misuse or both；&#xD;
&#xD;
          -  pregnancy or lactation；&#xD;
&#xD;
          -  vaccination against influenza within the last 12 months；&#xD;
&#xD;
          -  use of oral antibiotics, probiotics, prebiotics, synbiotics, drugs active on&#xD;
             gastrointestinal motility, or a laxative of any class within the last month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liegang Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Liegang Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

